U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07195825) titled 'A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease' on Sept. 10.
Brief Summary: The purpose of the study is to evaluate the safety and tolerability of BBM-P002 for stereotactic injection to treat participants with idiopathic Parkinson's Disease (PD) during the dose-limiting toxicity (DLT) observation period.
Study Start Date: Oct. 09
Study Type: INTERVENTIONAL
Condition:
PD
Intervention:
GENETIC: Injecting BBM-P002 into the bilateral putamen
BBM-P002 is an AAV-based gene therapy that delivers a therapeutic gene cassette into putamen for the treatment of Parkinson's D...